Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIg With or Without Cyclophosphamide in Pemphigus
NCT00483119Phase 2Terminated
- Sponsor
- NYU Langone Health
- Start
- Apr 2007
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cyclophosphamide in pemphigus vulgaris (PV) and pemphigus foliaceus (PF) (2 arms), sponsored by NYU Langone Health. Primary endpoints: Extent and Severity of Disease at 10 weeks and Serum Levels of Pemphigus Antibodies at 10 weeks. Started Apr 2007; status: terminated.
02
Drugs
cyclophosphamide
03
Conditions
pemphigus vulgaris (PV)pemphigus foliaceus (PF)
Beyond the preview
Go deeper on NCT00483119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00483119.